Tradeable Event
LIVE
--:--:--
Volume
$0
Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion
Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.
—
—
—
—
--:--:--
—
Blue Team
50%
Red Team
50%
$0 vol
Loading chart...
PAPER
LIVE
$
Avg price
50¢
Shares
Potential return
$20.00 (+100%)
BLUE TEAM
Blue Team
+0.00%
wins
—
EPOCH WINS
RED TEAM
Red Team
+0.00%
wins
Epoch History
No completed epochs yet
Recent Trades
Waiting for trades...
Event Feed
Monitoring headlines...
Buy Blue Team
$
Avg price
50¢
Shares
Potential return
$20.00 (+100%)